180 197

Cited 12 times in

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author한광협-
dc.contributor.author김태현-
dc.contributor.author박소희-
dc.date.accessioned2017-11-02T07:51:47Z-
dc.date.available2017-11-02T07:51:47Z-
dc.date.issued2017-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154057-
dc.description.abstractBACKGROUND AND AIMS: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40-70, compared to current practice (no screening). METHODS: A published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40-49, 50-59 and 60-69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82.5% and 17.5%, respectively). Based on a published seroepidemiology study, HCV prevalence was estimated at 0.60%, 0.80% and 1.53%, respectively. An estimated 71.7% of the population was screened. Post-diagnosis, 39.4% of patients were treated with a newly available all-oral direct-acting antiviral (DAA) regimen over 5 years. Published rates of sustained virologic response, disease management costs, transition rates and utilities were utilised. RESULTS: Screening resulted in the identification of 43,635 previously undiagnosed patients across all cohorts. One-time HCV screening and treatment was estimated to be cost-effective across all cohorts; predicted incremental cost-effectiveness ratios ranged from $5,714 to $8,889 per quality-adjusted life year gained. Incremental costs associated with screening, treatment and disease management ranged from $156.47 to $181.85 million USD; lifetime costs-offsets associated with the avoidance of end stage liver disease complications ranged from $51.47 to $57.48 million USD. CONCLUSIONS: One-time HCV screening and treatment in South Korean people aged 40-70 is likely to be highly cost-effective compared to the current practice of no screening.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntiviral Agents/therapeutic use-
dc.subject.MESHCost-Benefit Analysis-
dc.subject.MESHGenotype-
dc.subject.MESHHepacivirus*/classification-
dc.subject.MESHHepacivirus*/genetics-
dc.subject.MESHHepatitis C/diagnosis-
dc.subject.MESHHepatitis C/drug therapy-
dc.subject.MESHHepatitis C/epidemiology*-
dc.subject.MESHHepatitis C/virology-
dc.subject.MESHHepatitis C, Chronic/diagnosis-
dc.subject.MESHHepatitis C, Chronic/drug therapy-
dc.subject.MESHHepatitis C, Chronic/epidemiology-
dc.subject.MESHHepatitis C, Chronic/virology-
dc.subject.MESHHumans-
dc.subject.MESHMarkov Chains-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrevalence-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSeroepidemiologic Studies-
dc.titleEstimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorByungyool Jun-
dc.contributor.googleauthorTae Hyun Kim-
dc.contributor.googleauthorSohee Park-
dc.contributor.googleauthorThomas Ward-
dc.contributor.googleauthorSamantha Webster-
dc.contributor.googleauthorPhil McEwan-
dc.identifier.doi10.1371/journal.pone.0167770-
dc.contributor.localIdA04268-
dc.contributor.localIdA01082-
dc.contributor.localIdA01531-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid28060834-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Tae Hyun-
dc.contributor.alternativeNamePark, So Hee-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Tae Hyun-
dc.contributor.affiliatedAuthorPark, So Hee-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.titlePLoS One-
dc.citation.volume12-
dc.citation.number1-
dc.citation.startPagee0167770-
dc.identifier.bibliographicCitationPLOS ONE, Vol.12(1) : e0167770, 2017-
dc.date.modified2017-11-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
4. Graduate School of Public Health (보건대학원) > Graduate School of Public Health (보건대학원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.